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Chimeric HPVWe studied a panel of mutant viruses containing wild-type and chimeric capsid HPV16 and HPV18 proteins.
The mutant capsid protein expression, genome ampliﬁcation, and episomal maintenance were comparable
with the wild-type virus. However, the chimeric viruses varied in their titers from wild-type. We show that
the intertypical mutant chimeric capsid viruses, that L2 affects the structure of L1 and that L1 affects the
structure of L2 in the virion. These effects were measured using a panel of conformation-dependent
neutralizing L1 MAbs and an L2 capsid surface peptide derived neutralizing antibody. These data suggest that
variation of one capsid gene not only affects its own structure and antigenicity, but also affects the structure
and antigenicity of the other capsid protein. Implications of our data suggest that for the continued
effectiveness of a vaccine, variation in both capsid proteins need to be considered and not just the protein the
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Human papillomavirus (HPV) is the primary etiologic agent of
cervical cancer. The viral capsid is approximately 50 to 55 nm in
diameter, and has an icosahedral symmetry of T=7 (de Villiers et al.,
2004). The viral particle contains 360 copies of the major capsid
protein L1, organized into 72 pentameric capsomeres. The atomic
structure of a small, T=1HPV16 L1 virus-like particle (VLPs) has been
determined (Chen et al., 2000). Because VLPs, pseudoviruses (PsV)
and quasiviruses (QV) are structurally similar to native virus, they
have been used as surrogates for native virus in investigating the viral
life cycle, structure, and host immunity. Recombinant-derived
particles formed in monolayer cultures lack differentiation-depen-
dent temporally correct and regulated capsid protein interactions.
Therefore, these particles may or may not be accurate surrogates for
the native virus. The organotypic (raft) tissue culture system is still
the only in vitro method proven to reproducibly mimic epithelial
differentiation to the extent that the full HPV life cycle can be studied
and wherein infectious virions can be obtained from stratifying tissue
in a differentiation-dependent culture system (Meyers et al., 1992;
Ozbun, 2002a, 2002b; Song et al., 2010).Recent publications have demonstrated that the native virus
replicated in stratifying and differentiating host tissue differs in
signiﬁcant aspects from particles made using recombinant particles
(Conway et al., 2009a, 2009b). For example, when the two N-terminal
conserved HPV16 L2 cysteines were mutated in PsV or QV, the
particles produced were non infectious (Campos and Ozbun, 2009;
Gambhira et al., 2009). Moreover, when the same mutations were
tested in native viral particles produced in stratifying and differen-
tiating human epithelium, not onlywere themutant viruses infectious
but their titers were dramatically increased in some cases (Conway et
al., 2009a). Additionally, the maturation time required for monolayer-
culture derived PsV HPV16 is 24 h (Buck et al., 2005), but 20 days is
required for maturation of differentiation-dependent grown native
virus (Conway et al., 2009b). These brief examples suggest that the
genetics and biochemistry of viral synthesis differ in recombinant
particles formed within undifferentiating monolayer culture versus
native virus formed within differentiating host epithelia.
The HPV capsid genes have high sequence homology. A recent
manuscript described a series of intra- and/or inter-species cross-
reactive epitopes suggesting that cross-reactivity only loosely follows
phylogenetic relationships that are based on capsid gene sequence
homology (Rizk et al., 2008). An important question is whether or not
the sequence homology equates to similar requirements for virion
assembly and maturation. One way to test this is to use HPV mutant
constructs containing chimeric capsid genes. Recently, to test the
relationship between sequence homology and virion morphogenesis
we constructed a panel of mutant viruses containing wild-type and
chimeric HPV16 and HPV18 capsid proteins (Chen et al., 2010). While
aspects of their life cycles such as protein expression, genome
Fig. 1. L2 and L1 half and half chimeric mutants (Chen et al., 2010).
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affected by the chimeric capsid proteins, the chimeric viruses showed
variation in their viral titers. Due to the reduction of titers of some
chimeric viruses, we hypothesized that the capsid proteins could
mutually affect each other's structure–function in the viral particle,
therefore affecting infectivity.
Using VLPs, type-speciﬁc, conformation-dependent neutralizing
antibodies have been generated for neutralization and capsid structural
studies (Bishop et al., 2007; Christensen et al., 2001, 1996a; Culp et al.,
2007; Rizk et al., 2008).Most L1 conformation-dependentMAbs are able
to bind L1 VLPs as well as L1/L2 VLPs and virions. These data led to the
idea that L2 has little impact on the conformation of L1 within the VLPs
and virions. Studying the inhibition of PsV infection with a panel of
polyclonal antibodies raised from HPV16 L2 peptides, potential
neutralizing L2 sequences exposed on the capsid surface have been
mapped (Kawana et al., 2001; Pastrana et al., 2005). To test our
hypothesis that L1 and L2 canmutually affect each other's structure, we
used a panel of conformation-dependent neutralizing L1 MAbs and an
L2 capsid surface peptide derived neutralizing MAb and tested their
abilities to neutralize infection by HPV18/HPV16 chimeric capsid
protein mutant viruses. We observed with our intertypical chimeric
capsid mutant viruses that L2 can affect the structure of L1 and that L1
can affect the structure of L2 in the native virus.
Results
Using the HPV18 genome as the backbone, we recently showed
that genomes containing the intertypical exchange of HPV18 L1 with
the HPV16 L1 efﬁciently replicated and produced infectious virus;
however, genomes containing an intertypical exchange of HPV18 L2
for the HPV16 L2 failed to produce detectable infectious virus (Chen et
al., 2010). Expanding on this observation we studied a panel of eight
chimeric constructs of individual capsid proteins. Seven of these
mutants produced detectable infectious virus, but titers varied as
much as 200-fold between the mutants. Importantly, one mutant did
not produce detectable infectious virus (Chen et al., 2010). From these
studies we identiﬁed a type-speciﬁc domain at the N-terminus of the
L1 capsid protein of HPV18, which interferes with its ability to
cooperate with the HPV16 L2 protein to form infectious viral particles.
Deletion of this domain led to the cooperation of the HPV18 L1 protein
and HPV 16 L2 protein as measured by the production of infectious
progeny. However, this N-terminal sequence deletion of HPV18 L1
induced a change in the conformational structure as determined by
the loss of neutralization with HPV18 L1 conformation-dependent
neutralizing antibody (Chen et al., 2010). Based on the observed
results, we hypothesized that the differences we see in the viral titers
of the eight chimeric capsid mutants were related to changes in
structure imposed by one capsid protein on the other capsid protein.
Changes in L1 structure imposed by chimeric L2 proteins as determined
by neutralizing MAbs
To test our hypothesis that L2 structural alterations can affect the
conformation of L1, viral stocks were prepared by growing organo-
typic cultures of human keratinocyte cell lines infectedwithwild-type
HPV16, HPV18, and with each of the eight chimeric mutant viruses
(Fig. 1) (Chen et al., 2010). The chimeric viruses were made using
HPV18 as the backbone and exchanging half of L2 or L1 with the
corresponding half from HPV16 (Fig. 1) (Chen et al., 2010). A
homologous sequence in the middle of the L2 and L1 proteins of
HPV18 and HPV16was used for the chimeric junction, allowing for the
maintenance of sequence and structure around the junction sites. For
L1 this region is in the C-terminal portion of beta sheet F (Fig. 2).
Determining the structure of L2 has been difﬁcult (Chen et al., 2010)
therefore we chose a homologous sequence in the center of the
protein to avoid reported functional domains (Becker et al., 2003;Bossis et al., 2005; Da Silva et al., 2001; Day and Schiller, 2006; Finnen
et al., 2003; Florin et al., 2002, 2004; Giroglou et al., 2001; Graham,
2006; Heino et al., 2000; McMillan et al., 1999; Okun et al., 2001;
Roden et al., 1994; Yang et al., 2003). Multiple stocks of each mutant
virus were prepared, infectivity tested using a previously described
Limited Dilution RT-PCR titering assay (Alam et al., 2008; Conway et
al., 2009a, 2009b; McLaughlin-Drubin et al., 2004; McLaughlin-Drubin
and Meyers, 2004, 2005; McLaughlin-Drubin et al., 2003; Meyers et
al., 2002, 1997), and reproducible titers were observed for indepen-
dently derived stocks of each virus (Table 1).
We predicted that the variations observed in the viral titers of raft
tissues infected with one of the eight chimeric HPVs were due to a
change in structure of the wild-type capsid protein induced by the
chimeric capsid protein. To test our prediction we used conformation-
dependent L1-reactive monoclonal antibodies (MAbs) in the Limited
Dilution RT-PCR assays. To test whether the capsid structure had been
affected, HPV16 and HPV18 L1-reactive conformation-dependent
antibodies H16.7E, H16.V5, H18.J4, and H18.K2 were tested for their
ability to neutralize infection by HPV18-L2(18)L1(16/18), HPV18-L2
(18)L1(18/16), HPV18-L2(16)L1(16/18), HPV18-L2(16/18)L1(18),
HPV18-L2(18/16)L1(18), HPV18-L2(16/18)L1(16), and HPV18-L2
(18/16)L1(16) (Fig. 1). The conformation-dependent binding and
neutralizing activity of all four MAbs has been previously character-
ized (Bishop et al., 2007; Chen et al., 2010; Christensen et al., 2001,
1996b; Culp et al., 2007; Rizk et al., 2008). HPV16 L1 conformation-
dependent neutralizing MAb H16.7E binds to the BC capsid loop
(Christensen et al., 2001, 1996b; Culp et al., 2007) and H16.V5 binds to
the FG loop and to a lesser extent the HI loop (Christensen et al., 2001,
1996b). In our chimeric virus the epitope for H16.7E would be present
in the N-terminal half of HPV16 L1, whereas the epitope for H16.V5
would be present in the C-terminal half of HPV16 L1 (Fig. 2). In
contrast to HPV16 L1-reactive MAbs, the binding regions for HPV18
L1-reactive MAbs H18.J4 and H18.K2 have not yet been mapped.
The titers for wild-type HPV18 and HPV16 were reproducibly high,
measuring 7500 and 10,000, respectively (Table 1). Type-speciﬁc,
conformation-dependent MAbs H18.J4 and H18.K2 neutralized infec-
tion by wild-type HPV18. Likewise infection by wild-type HPV16 was
neutralized by type-speciﬁc, conformation-dependent MAbs H16.7E
and H16.V5 (Table 1 and Fig. 2). Therefore, all four MAbs were type-
speciﬁc in their ability to neutralize infection. We then proceeded to
perform neutralization assays on the viral stocks of each chimeric virus,
with the exception of HPV18-L2(16)|L1(18/16), which never produced
a stock of detectable infectious virus (Table 1). Of the other three
chimeras that contained a wild-type L2 and a chimeric L1 protein,
HPV18-L2(18)L1(16/18), HPV18-L2(18)L1(18/16), and HPV18-L2(16)
Fig. 2. Position of the chimeric junction, HPV16 L1-reactive conformation-dependent MAb epitopes, structural motifs and sequence homology of HPV18 and HPV16 L1 proteins. The
L1 protein amino acid sequences for HPV18 and HPV16 are aligned. Sequence numbering begins with the ‘consensus’methionines used for producing VLPs, PsV, and QV (Chen et al.,
2010). The extended N-terminal sequences present in native viruses are given as prime numbers, 1′–61′ for HPV18 and 1′–26′ for HPV16. Structural motifs are marked underneath
the appropriate sequences (Chen et al., 2000) by arrows for ß-sheets and bold lines for helices. HPV16 L1-reactive conformation-dependent MAb epitopes (Christensen et al., 2001;
Culp et al., 2007) are outlined by dashed line boxes. The chimeric junction, LRREQ amino acids 250–254 is outlined by a solid box.
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et al., 2010). As expectedMAb H16.7E was able to neutralize HPV18-L2
(18)L1(16/18) and HPV18-L2(16)L1(16/18) both of which contain the
N-terminal half of the HPV16 L1 protein containing the H16.7E epitope.
Both of these chimeric viruses contained the C-terminal half of the
HPV18 L1 and as we expected, their infectivity was not neutralized by
type-speciﬁc H16.V5 (Table 1). Conversely, the chimera HPV18-L2(18)
L1(18/16) is just the opposite having only the C-terminal half of the
HPV16 L1 protein. Since the type-speciﬁc H16.V5 has its epitope on the
C-terminal half of L1, it could neutralize infection by this mutant virus
(Table 1). As expected, H16.7E did not neutralize HPV18-L2(18)L1(18/Table 1
L1-speciﬁc monoclonal antibody neutralization of chimeras.
HPV chimera Titer ave/SDa H18.J4 H18.K2 H16.7E H16.V5
Wt HPV18 8125/1157 +b + − −
Wt HPV16 10,000/0 −c − + +
HPV18-L2(18)L1(16) 10,000/0 − − + +
HPV18-L2(16)L1(18) 1/4.5 + + − −
HPV18-L2(18)L1(16/18) 20/0 − − + −
HPV18-L2(18)L1(18/16) 5000/0 + − − +
HPV18-L2(16)L1(16/18) 1000/0 − − + −
HPV18-L2(16)L1(18/16) 0/0 NDd ND ND ND
HPV18-L2(16/18)L1(18) 100/0 + − − −
HPV18-L2(18/16)L1(18) 20/45 − − − −
HPV18-L2(16/18)L1(16) 100/0 − − − +
HPV18-L2(18/16)L1(16) 73/46 − − + −
a Average titer/standard deviation of at least three separate virus stock preparations.
b MAb was able to neutralize infection.
c MAb was not able to neutralize infection.
d Not done, no infectious virus.16). Of these three chimeric viruses only infection by HPV18-L2(18)L1
(18/16) was neutralized by MAb H18.J4. H18.J4 did not neutralize
HPV18-L2(18)L1(16/18) and HPV18L2(16)L1(16/18) suggesting that
the H18.J4 epitope lay on the N-terminal half of the HPV18 L1 protein.
Interestingly,MAbH18.K2hadnoeffect on the infectivity of any of these
three chimeric viruses. This would suggest either that the epitope was
around the junction and subtle conformational differenceswere enough
to prevent its binding, or that the L1 protein differed enough in its
overall structure as a result of the chimeric structure to prevent binding.
Next we evaluated the neutralization activities of H16.7E, H16.V5,
H18.J4, andH18.K2on infectivity by themutant viruses containing awild-
type L1 protein and a chimeric L2 protein. All the neutralization assays
were done using a 1:20 dilution of the viral stock preincubated with a
type-speciﬁc MAb and infectivity measured using the Limited Dilution
RT-PCR titering assay. Thismeans that amuch lower amount of infectious
chimeric virus was used per neutralization than used with the wild type
virus, so it would be expected that the MAbs would neutralize the
chimeric stocks. Based on their ability to neutralize infection by the high
titerwild-typeHPV16andHPV18virus stocks,weexpected that the type-
speciﬁc L1-reactive conformation-dependent MAbs would neutralize
infection of viruses containing wild-type L1 proteins. H16.7E and H16.V5
were incapable of neutralizing infection by viruses containing awild-type
HPV18 L1. Similarly H18.J4 and HPV18.K2 were incapable of neutralizing
infection by viruses containing a wild-type HPV16 L1 (Table 1).
When H16.7E and H16.V5 were tested with HPV18-L2(16/18)L1
(16) only H16.V5 was able to neutralize infection. However, when
H16.7E and H16.V5 were tested with HPV18-L2(18/16)L1(16) only
H16.7E was able to neutralize infection. This was unexpected since
both viruses have a wild-type HPV16 L1 protein. These results suggest
that the chimeric L2 impacted the structure of L1 inducing a loss of
Table 3
L2-speciﬁc antibody RG-1 neutralization of chimeras.
HPV chimera RG-1
Wt HPV18 +a
Wt HPV16 +
HPV18-L2(18)L1(16/18) −b
HPV18-L2(18)L1(18/16) −
HPV18-L2(16)L1(16/18) +
HPV18-L2(16)L1(18/16) NDc
HPV18-L2(16/18)L1(18) +
HPV18-L2(18/16)L1(18) +
HPV18-L2(16/18)L1(16) +
HPV18-L2(18/16)L1(16) +
a MAb was able to neutralize infection.
b MAb was not able to neutralize infection.
c Not done, no infectious virus.
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tested with HPV18-L2(16/18)L1(18) and HPV18-L2(18/16)L1(18) a
similar result was observed, except that H18.J4 was only able to
neutralize infection by HPV18-L2(16/18)L1(18) and neither HPV18-
L2(16/18)L1(18) nor HPV18-L2(18/16)L1(18) were neutralized by
H18.K2 (Table 1). Again this suggests that the chimeric L2 impacted
the structure of L1 inducing a loss of function phenotype in the
infectivity neutralization assay.
To further support this observation, we used two additional
conformation-dependent HPV16 L1-reactive MAbs, H16.J4 and
H16.9A. These two MAbs were made using L1-only VLPs (Culp et al.,
2007).When theseMAbswere initially characterized itwas found that
while they bound efﬁciently to L1 only VLPs, binding was signiﬁcantly
decreased when VLPs containing L1 and L2 were used (Culp et al.,
2007). In linewith this observationneitherH16.J4 norH16.9Awas able
to neutralize infection by wild-type HPV16 (Table 2). Surprisingly,
when tested on infectivity by HPV18-L2(16/18)L1(16) and HPV18-L2
(18/16)L1(16), both MAbs H16.J4 and H16.9A neutralized infection.
Again this suggests that the chimeric L2 protein impacts the structure
of the wild-type L1 protein, but in this case inducing a gain of function
phenotype in the infectivity neutralization assay.
Changes in L2 structure imposed by chimeric L1 proteins as determined
by a neutralizing MAb
After observing that a chimeric L2 protein could impact the
structure of a wild-type L1 protein in HPV infectious particles we next
were interested in testing whether a chimeric L1 protein could change
the structure of the L2 protein within the virus. For these assays, we
used the L2-reactive MAb RG-1 (Gambhira et al., 2007a; Pastrana et
al., 2005). RG-1 was raised against the 17 to 36 amino acid peptide of
HPV16 L2. This region shows high sequence homology among high-
risk HPVs (Pastrana et al., 2005). RG-1 has also been shown to cross-
react with HPV types other than HPV16 (Gambhira et al., 2007b;
Kawana et al., 1999). Infectivity of both wild-type HPV16 and HPV18
were neutralized by RG-1 (Table 3). Infectivity of all four mutant
viruses containing a chimeric L2 protein, HPV18-L2(16/18)L1(18),
HPV18-L2(18/16)L1(18), HPV18-L2(16/18)L1(16), and HPV18-L2
(18/16)L1(16) were neutralized by RG-1 (Table 3). This was expected
since RG-1 could neutralize both wild-type HPV16 and HPV18
infection. However, when RG-1 was tested for its ability to neutralize
infection of the mutant viruses containing a wild-type L2 protein and
a chimeric L1 the results were mixed. RG-1 was effective in
neutralizing infection by HPV18-L2(18)L1(16/18) and HPV18-L2
(18)L1(18/16), but not infection by HPV18-L2(16)L1(16/18)
(Table 3). Similar to what was observed with L1-reactive MAbs the
results obtained with the L2-reactive MAb suggest that chimeric L1
impacts the structure of wild-type L2 in the native viral particle. The
mutant HPV18-L2(16)L1(18/16) never produced infectious stocks of
virus so it could not be tested in the neutralization assays.
Discussion
VLPs comprised of full-length HPV16 L1 have not been crystallized.
A deletion of ten amino acids from the ‘consensus’ methionine was
necessary to assemble VLPs that were competent for crystallographicTable 2
H16.J4 and H16.9A are able to neutralize L2 chimeras but not wild-type HPV16.
HPV chimera H16.J4 H16.9A
Wt HPV16 −a −
HPV18-L2(16/18)L1(16) +b +
HPV18-L2(18/16)L1(16) + +
a MAb was not able to neutralize infection.
b MAb was able to neutralize infection.analysis, resulting in a T=1 icosahedral lattice made from 12 L1
pentamers, as opposed to the native T=7 icosahedral lattice made
from 72 L1 pentamers (Chen et al., 2000). This structure was quite an
accomplishment and allowed the ﬁeld to make further hypotheses
regarding the structure of HPV. However, the small size of the T=1
particle and lack of disulﬁde bonds suggest that the model may not be
representative of all detailed temporal interactions that occur between
andwithin the L1pentamers of native virions duringmorphogenesis in
stratifying and differentiating epithelial tissue. The recently published
high resolution bovine papillomavirus type 1 (BPV-1) cryo-electron
microscopy (cryo-EM) structure does provide more insight into intra-
and inter-pentameric L1 interactions, but provides no information on
interactions with the L2 capsid protein (Wolf et al., 2010).
HPV L1 pentamers are thought to form a network of intra- and
interpentameric disulﬁde bonds to stabilize the capsid (Buck et al.,
2005; Fligge et al., 2001; Kondo et al., 2007; Sapp et al., 1998). The
cryo-EM structure of BPV-1 has an interpentameric L1 disulﬁde bond
between two cysteine residues that are highly conserved among
papillomaviruses, including HPVs (Wolf et al., 2010). BPV-1 also
contains an intrapentameric disulﬁde bond between two cysteine
residues that are not present in HPVs (Wolf et al., 2010).
L1 is sufﬁcient to produce monolayer culture-derived particles;
however, L2 has been shown to affect theﬁnal structure of the virion, in
addition to enhancing infectivity and DNA encapsidation (Holmgren
et al., 2005; Kirnbauer et al., 1992; Kondo et al., 2007). Papillomavirus
capsids also contain an unknown amount of the minor capsid protein
L2. Early cryo-EM studies of native BPV1 virus suggested that one L2
protein occludes the center of each pentavalent capsomere, totaling 12
L2 proteins per virion (Trus et al., 1997). This L1:L2 ratio of 30:1 was
supported by SDS-PAGE analyses of L1/L2 VLPs (Bossis et al., 2005;
Hagensee et al., 1993; Kirnbauer et al., 1993; Volpers et al., 1994),
however SDS-PAGE analysis of native HPV11 virions, biochemical
analyses of HPV11 L1/L2 proteins, and cryo-EM images of HPV16 PsV
suggest that papillomavirus particles can contain 36 and asmuch as 72
L2 proteins per particle (Buck et al., 2008; Doorbar and Gallimore,
1987; Finnen et al., 2003). However, recent high-resolution cryo-EM
image reconstructions of native BPV failed to detect L2 protein density,
suggesting that L2 signal may be averaged out of the reconstruction
and that it is not maximally packaged into native virions ormay be too
mobile to visualize (Buck et al., 2008; Wolf et al., 2010).
Also, within the virion is a histone-associated, circular viral
genome, which has been shown to alter the ﬁnal structure of the
virion (Fligge et al., 2001; Sapp et al., 1998). In addition to L2 and viral
genomes it is also probable that unknown viral and/or cellular
proteins/factors such as molecular chaperones and karyopherins may
exist which inﬂuence the ﬁnal structure of native virions (Bird et al.,
2008; Chromy et al., 2003). Our laboratory has recently demonstrated
the presence of two different species of the HPV16 L1 protein in native
virions that is not present in quasivirus particles (Conway et al.,
2009b). The effect if any of having two species of the L1 protein on viral
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with both species of L1 localize to the gradient fractions exhibiting the
highest concentration of mature infectious virions. In addition, virions
isolated from these fractions exhibit a greater structural stability when
compared to ‘mature’ QV (Conway et al., 2009b).
L2 appears to interact with L1 capsomeres and not with preformed
L1 VLPs, suggesting co-assembly of L1 and L2 into a virus particle
(Finnen et al., 2003). Since L2 enhances assembly of L1 capsomeres in
the absence of disulﬁde bonding, hydrophobic interactions between L2
and L1 are likely to initiate during early assembly events (Ishii et al.,
2005). During differentiation co-assembly would require a regulated
process mediated by interactions between the two proteins. Future
investigations likely will discover other viral and/or cellular factors that
are necessary for the proper assembly of virions associated with
regulation of redox states within the cell, proper cellular localization
and initial interaction of capsid proteins, the correct formation and
regulation of disulﬁde bonds, and regulation of capsid protein
expression. Invitro, theonly systemthat canmimic all these interactions
and mechanisms is the human epithelial organotypic culture allowing
for complete stratiﬁcation and differentiation of the natural host tissue.
Our laboratory's previous studies showed that while the HPV16 L1
protein could cooperate with the HPV18 L2 protein to produce
infectious virus, the HPV18 L1 protein could not cooperate with the
HPV16 L2 protein thereby failing to produce infectious virus. A region
at theN-terminus of theHPV18 L1proteinwas shown tobe responsible
for the inability to cooperate with the HPV16 L2 protein. Removal of
this N-terminal region allowed for HPV18 L1 and HPV16 L2 proteins
producewild-type levels of infectious virus and these chimeric viruses
exhibit subtle structural changes as measured by MAb neutralization
activity (Chen et al., 2010). A panel of mutant viruses containing wild-
type and chimeric HPV18 and HPV16 capsid proteins exhibited
variation in their viral titers, while measurements of different aspects
of their life cycles did not provide an answer to the variation in titers
(Chen et al., 2010). We believed that due to the chimeric nature of one
of the capsid proteins, subtle changes in the structure of the other
capsid protein had occurred. Another possibility for the L2 chimerics is
that they are able to occlude the binding sites for the L1MAbs, however
we feel this possibility is less likely.Wemeasured the presence of these
changes by their effect on the neutralization activity of MAbs. Our
results strongly suggest that the structure of one capsid protein
affected the structure of the other capsid protein.
In our studywe hypothesized that the capsid proteins couldmutually
affect each other's structure in the viral particle and therefore affect titers.
Our results supported this hypothesis showing not only a loss of
neutralization (loss of function) but also gain of neutralization (gain of
function) affectedby thepresenceof amutant L2 capsidprotein. Similarly,
the presence of a mutant L1 protein in the assembled viral particles
affected the ability of an L2-reactive MAb to neutralize infection. The
MAbs used in this study probably all react with surface exposed epitopes
on the capsid. It is possible that a disturbance in structure equivalent to
what is present in the chimeric virusesmight be too defective tomaintain
themselves in a vaccinated population. Continued monitoring of
vaccinatedpopulations for viral infection iswarrantednot only to identify
increases in infection by variants and non vaccine types, but also to
identify waning of the vaccinated host to block infection. Our data
suggests that it is not only mutations in the particular vaccine directed
capsid protein L1 or L2 thatmay alter the effectiveness of the vaccine, but
also mutations in the capsid protein that is not part of the vaccine.
Materials and methods
Chimeric HPV genomes and organotypic raft cultures
Chimeric mutant HPV genomes were described previously (Chen
et al., 2010). Organotypic raft cultures were grown as previously
described (Meyers et al., 2002).Preparation of virus stocks
Virus stocks of each HPV chimera were prepared by peeling the
epithelial tissue away from the collagen of three organotypic rafts. The
peeled epithelial tissues were homogenized in 0.6 ml of ice-cold 1 M
NaCl/0.05 M Na–Phosphate Buffer with a 7.5 ml homogenizer. The
homogenizer was washed twice with 200 μl 1 M NaCl/0.05 M Na–
Phosphate Buffer, pH 8. The homogenized viral solution was
centrifuged at 10.5 k for 10 min at 4 °C and the supernatant
transferred to a 1.8 ml Nalgene cryovial. Each virus stock was made
from three raft culture tissues and all stocks were stored at −20 °C.
HPV infection and neutralization assays
The infectivity measurement of chimeric HPV used the Limited
Dilution RT-PCR titering assay as described previously (Alam et al.,
2008; Conway et al., 2009a, 2009b; McLaughlin-Drubin et al., 2004;
McLaughlin-Drubin and Meyers, 2004, 2005; McLaughlin-Drubin et
al., 2003; Meyers et al., 2002, 1997) using HaCaT cells, an
immortalized human keratinocyte cell line (kindly provided by
Norbert Fusenig, German Cancer Research Center). The virus titer
was determined to be the last dilution at which the viral E1–E4 spliced
transcript could be detected.
Neutralization assays were performed by infecting HaCaT cells
with a 1:20 diluted viral sample that had been preincubated with
either conformation-dependent neutralizing L1 monoclonal antibo-
dies (MAbs) or the L2 surface peptide derived MAb diluted 1:20 in
HaCaT culture medium as previously described (Chen et al., 2010;
Conway et al., 2009a, 2009b; McLaughlin-Drubin et al., 2004;
McLaughlin-Drubin and Meyers, 2005; McLaughlin-Drubin et al.,
2003). HPV18 and HPV16 L1 conformation-dependent, neutralizing
MAbs H18.J4, H18.K2, H16.V5, H16.7E, H16.9A and H16.J4 were used
(Bishop et al., 2007; Christensen et al., 2001, 1996a; Culp et al., 2007;
Rizk et al., 2008). In addition, an HPV16 L2-reactive monoclonal
antibody RG-1 was used (Gambhira et al., 2007a; Pastrana et al.,
2005). Following preincubation, HaCaT cells were incubated with the
virus–antibody mixture for 2 days. Total RNA was then extracted and
RT-PCR was performed as described (Chen et al., 2010; Conway et al.,
2009b).
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